Updated:
Acorn Bioventures
Acorn Bioventures is a New York-based private equity firm focused on venture and growth investments.
Acorn Bioventures
Acorn Bioventures focuses on investments in private and small-capitalization biotech, specialty pharma, and medical device companies. The firm has made 27 investments, including a Series D investment in Neuron23 on June 24, 2025. Acorn Bioventures has facilitated 9 portfolio exits, with Verona Pharma being their most recent exit on October 07, 2025.
General information
Firm type
Venture Capital
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, United States
Sector focus
Frequently asked questions
What stages does Acorn Bioventures target?
The firm lists coverage of seed, expansion, late-stage growth, PIPEs, and pre-IPO transactions.
Where is Acorn Bioventures headquartered?
New York, United States.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: